Glycomics Market – Global Industry Size, Share, Trends, Opportunities, & Forecast, Segmented By Product (Enzymes, Kits, Reagents, Instruments), By Application (Drug Discovery & Development, Diagnostics, Others), By End-User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Biopharmaceutical Companies, CROs), By Region, Competition, 2020-2030F

Market Overview

The Global Glycomics Market, valued at USD 1.94 Billion in 2024, is projected to experience a CAGR of 14.59% to reach USD 4.39 Billion by 2030. Glycomics is defined as the comprehensive study of glycomes, encompassing all glycan structures, whether free or complex molecules, within an organism or cell, to understand their genetic, physiological, and pathological aspects. The global glycomics market growth is significantly driven by the increasing prevalence of chronic diseases, necessitating advanced diagnostic and therapeutic tools. Furthermore, continuous advancements in glycomics technologies and analytical techniques, coupled with rising investments in drug discovery and development by biopharmaceutical companies, propel market expansion.

According to the Canadian Glycomics Network (GlycoNet), in 2023, it invested $78.4 million domestically in glycomics research, funding 138 projects. A significant challenge impeding market expansion is the inherent structural complexity and vast diversity of glycan structures, which complicates comprehensive analysis and standardization efforts.

Key Market Drivers

The escalating global burden of chronic and infectious diseases significantly propels the glycomics market, as glycans are integral to disease pathology, immune modulation, and pathogen interactions, necessitating advanced diagnostic and therapeutic tools. Conditions such as cancer, autoimmune disorders, and metabolic diseases, including diabetes, demand sophisticated glycomics-based solutions for early detection and targeted interventions. According to the International Diabetes Federation, in 2023, an estimated 537 million adults aged 20-79 years were living with diabetes worldwide, underscoring the substantial patient population requiring improved approaches to disease management. This pervasive disease prevalence directly stimulates demand for glycomics research and applications, fostering the discovery of novel glycan biomarkers and the development of targeted glycan-based drugs and vaccines to address critical unmet medical needs.

Concurrently, profound technological innovations in glycomics analytical platforms are actively shaping market expansion by enabling more precise characterization of intricate glycan structures, which is crucial for elucidating their biological roles and disease implications. These advancements encompass improvements in mass spectrometry, high-performance liquid chromatography, and advanced sequencing techniques, all offering enhanced sensitivity, resolution, and throughput. For instance, according to Agilent Technologies, in February 2023, the introduction of its AdvanceBio Gly-X N-glycan prep with InstantPC kit streamlined glycan analysis, facilitating rapid N-glycan release, labeling, and subsequent analysis within less than one hour. Such sophisticated platforms accelerate biomarker discovery, expedite biopharmaceutical development, and foster the adoption of personalized medicine, thereby translating complex glycomics data into actionable clinical insights. Furthermore, the robust financial backing for glycomics research further supports market growth. According to the Institute for Glycomics Annual Report, in 2023, its researchers secured over $7,083,316 in research grant funding and an additional $9,586,705 in industry, philanthropic, and other support, signifying substantial investment in the field.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding market expansion stems from the inherent structural complexity and vast diversity of glycan structures. This biological intricacy profoundly complicates comprehensive analysis and standardization efforts essential for advancing glycomics applications. The extensive range of glycan configurations and their context-dependent roles necessitate highly specialized and often costly analytical techniques, leading to prolonged research and development cycles.

This complexity directly hampers the growth of the Global Glycomics Market by escalating the financial and temporal investment required for glycan-based drug discovery, diagnostics, and therapeutics. Developing robust, standardized platforms for glycan profiling and characterization becomes exceptionally resource-intensive. According to BIOTECanada, in December 2024, GlycoNet announced a new investment of $12 million over the next two years for 21 research projects focused on tackling health challenges through glycomics. This substantial ongoing investment by industrial networks underscores the significant financial commitment necessary to navigate the intricate landscape of glycoscience, thereby increasing the barrier to entry and slowing the pace of commercialization within the market.

Key Market Trends

The Global Glycomics Market is being significantly shaped by the integration of advanced computational methods and the increasing industrial demand for glycan analysis in drug production.

The integration of artificial intelligence and machine learning in glycan data analysis represents a transformative trend, enabling researchers to process and interpret the vast, complex datasets generated from glycomics studies with greater efficiency and accuracy. These technologies are crucial for identifying patterns and correlations in glycan structures that were previously challenging to detect. For example, according to GlycanML: A Multi-Task and Multi-Structure Benchmark for Glycan Machine Learning, published on arXiv in May 2024, machine learning models are being developed to predict glycan taxonomy, immunogenicity, glycosylation types, and protein-glycan interactions across diverse tasks. This analytical capability accelerates biomarker discovery and therapeutic development by translating complex glycomics information into actionable insights.

Concurrently, the rising industrial application of glycan profiling in biologics manufacturing is driving market expansion as pharmaceutical companies increasingly recognize the critical role of glycosylation in the efficacy, safety, and stability of therapeutic proteins. Stringent regulatory requirements for detailed glycan characterization of biologics, particularly monoclonal antibodies, necessitate robust profiling methods for quality control and process optimization. This emphasis is evident as Precision Biologics announced in April 2025 that it would present data on a new antibody-drug conjugate, PB-223 ADC, at the American Association for Cancer Research conference, underscoring the continuous need for thorough glycan characterization in novel therapeutic development and production. Such advancements help ensure therapeutic equivalence for biosimilars and optimize drug formulations. Furthermore, the Mizutani Foundation for Glycoscience, supporting research in this field, received 122 grant applications from 26 countries in 2024, awarding approximately 70 million yen in total to 16 projects, demonstrating substantial global investment in glycomics research and its industrial implications.

Segmental Insights

The Enzymes segment is experiencing rapid growth within the Global Glycomics Market due to its indispensable role across glycan-based research, diagnostics, and drug discovery. Enzymes are crucial for the precise synthesis, modification, and detailed analysis of complex carbohydrate structures, enabling deeper understanding of glycosylation's impact on biological processes. This growth is further propelled by advancements in enzyme engineering, leading to more efficient and specific tools essential for developing novel glycoprotein-based therapeutics and identifying disease biomarkers. Increased research and development investments by pharmaceutical and biotechnology companies, supported by initiatives from institutions like the National Institutes of Health, underscore the critical utility of enzymes in exploring glycan functions and their therapeutic potential.

Regional Insights

North America leads the global glycomics market, primarily due to its sophisticated research infrastructure and substantial federal funding for glycomics projects. This region benefits from significant investments in research and development by numerous pharmaceutical and biotechnology companies, which drives innovation in drug discovery and personalized medicine. Furthermore, a favorable regulatory environment and robust intellectual property protections encourage the commercialization of glycomics-based products. Institutions such as the National Institutes of Health actively support glycomics studies, fostering a conducive ecosystem for technological advancements and collaborations between academic institutions and industry players.

Recent Developments

• In December 2024, GlycoNet, in collaboration with its partner organizations, allocated an investment of $12 million to 21 glycomics research teams across Canada. This funding initiative was directed toward deepening the understanding of glycans and supporting the creation of novel instruments, medications, vaccines, and diagnostic tools. The collaborative effort aimed to address pressing health challenges by harnessing the potential of glycomics research. This investment highlights ongoing efforts by research networks and their partners to drive innovation and expand the practical applications of glycobiology within the global market.

• In July 2024, Pentixapharm AG, a clinical-stage biotechnology company, completed the acquisition of the target discovery business from Glycotope GmbH. This strategic move expanded Pentixapharm's radiopharmaceutical pipeline with Glycotope's portfolio of preclinical antibodies, which are designed to target various oncology targets. The acquired assets included Glycotope's proprietary GlycoTarget database, laboratories, and cell banks. This collaboration strengthens the development of novel cancer therapies by focusing on tumor-associated carbohydrate structures, an area central to advancing glycomics-based therapeutic strategies.

• In May 2024, Agilent Technologies launched its GlycoBiosign 2.0 Kit, a new product directly impacting the global glycomics market. This diagnostic tool received FDA clearance for the early detection of pancreatic cancer, demonstrating a diagnostic accuracy of 94%. The kit represents an advancement in leveraging glycan analysis for disease identification, offering a specific application within diagnostics. The introduction of such a specialized tool aids healthcare professionals in the timely diagnosis of a challenging cancer, underscoring the increasing integration of glycomics into clinical practice.

• In May 2024, GlycoNex, Inc., a biotechnology company specializing in glycan-focused cancer immunotherapies, actively sought new collaborations at the BIO International Convention. The company showcased its lead project, GNX102, an antibody-drug conjugate (ADC) designed to specifically target atypical sugar molecules present on cancer cells. Having successfully completed Phase 1 clinical trials, this therapeutic candidate demonstrates the potential of glycomics in developing targeted oncology treatments. GlycoNex’s pursuit of partnerships aimed to further advance its innovative anti-cancer pipeline, emphasizing the importance of strategic alliances in the glycomics sector.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Merck KgaA
• Agilent Technologies Inc.
• Bruker Corporation
• New England Biolabs Inc.
• Shimadzu Corporation
• Waters Corporation
• Takara Bio USA Inc
• Asparia Glycomics
• RayBiotech Life, Inc.

Report Scope:

In this report, the Global Glycomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Glycomics Market, By Product:

o   Enzymes

o   Kits

o   Reagents

o   Instruments

• Glycomics Market, By Application:

o   Drug Discovery & Development

o   Diagnostics

o   Others

• Glycomics Market, By End Use:

o   Academic & Research Institutes

o   Pharmaceutical & Biotechnology Companies

o   Biopharmaceutical Companies

o   CROs

• Glycomics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Glycomics Market.

Available Customizations:

Global Glycomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Glycomics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]